AVITA Medical Inc

Research AVITA Medical Inc (RCEL) on Bullrun: market cap USD 324.73M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 324.73M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 71.61M-USD 48.59M-USD 32.20M82.1%-1.74USD 10.24MUSD 42.98M-USD 16.65M
FY2024USD 64.25M-USD 61.85M-USD 58.11M85.8%-2.39USD 14.05MUSD 42.25MUSD 4.50M
FY2023USD 50.14M-USD 35.38M-USD 39.39M84.5%-1.4USD 22.12MUSD 39.81MUSD 49.06M
FY2022USD 34.42M-USD 26.67M-USD 19.54M82.4%1.07USD 18.16MUSD 532.00KUSD 84.74M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 324.73Mn/an/an/a
20252025-12-31USD 105.47Mn/an/an/a
20242024-12-31USD 337.33Mn/an/an/a
20232023-12-29USD 350.56Mn/an/an/a
20222022-12-30USD 165.20Mn/an/an/a
20212021-12-31USD 298.61Mn/an/an/a

About AVITA Medical Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is AVITA Medical Inc's market cap?

AVITA Medical Inc's market capitalization is USD 324.73M.

What does AVITA Medical Inc do?

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.